https://www.selleckchem.com/products/salinomycin.html alone. 4 TECHNICAL EFFICACY STAGE 2. 4 TECHNICAL EFFICACY STAGE 2.In this special issue of the American Journal of Medical Genetics, Part C, we explore the ever-expanding field of Ophthalmic Genetics. The eye is unique among organs for its accessibility to physical examination, permitting exploration of every tissue by slit lamp microscopy, ophthalmoscopy, and imaging including color and autofluorescent photography, ultrasound, optical coherence tomography (OCT), electrophysiology, and adaptive optics confocal and scanning laser ophthalmoscopy. This accessibility permits a variety of surgical and nonsurgical treatments, including the first FDA-approved gene therapy, voretigene neparvovec-rzyl for RPE65-associated Leber Congenital Amaurosis. In this issue, we sought to provide a survey highlighting how heritable ophthalmic disorders are recognizable and accessible to clinical geneticists as well as ophthalmologists.Our experiments have previously demonstrated that rutin (RUT) can improve myocardial damage caused by pirarubicin (THP). However, the underlying molecular mechanisms remain uncertain. In this study, we developed an microRNA (miRNA) chip by replicating the rat model of THP-induced myocardial injury and identified miR-22-5p and the RAP1-member of RAS oncogene family/extracellular regulated protein kinases (RAP1/ERK) signaling pathway as an object of study. Also, in vivo experiments demonstrated that THP caused abnormal changes in the electrocardiogram, cardiac function, and histomorphology in rats (P  less then  .01). THP also reduces the expression of miR-22-5p (P  less then  .01) and increases the levels of RAP1/ERK signaling pathway-related proteins (P  less then  .01, P  less then  .05). RUT significantly improved THP-induced myocardial damage (P  less then  .01), increased the expression of miR-22-5p (P  less then  .01), and decreased the levels of RAP1/ERK signaling pathway-related proteins (P  less